412 related articles for article (PubMed ID: 32636055)
1. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
4. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P
Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419
[TBL] [Abstract][Full Text] [Related]
5. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
6. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J
J Allergy Clin Immunol; 2020 Jul; 146(1):137-146.e3. PubMed ID: 32470486
[TBL] [Abstract][Full Text] [Related]
7. "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.
Kale SD; Mehrkens BN; Stegman MM; Kastelberg B; Carnes H; McNeill RJ; Rizzo A; Karyala SV; Coutermarsh-Ott S; Fretz JA; Sun Y; Koff JL; Rajagopalan G
Front Immunol; 2020; 11():1311. PubMed ID: 32676080
[TBL] [Abstract][Full Text] [Related]
8. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
Wu D; Yang XO
J Microbiol Immunol Infect; 2020 Jun; 53(3):368-370. PubMed ID: 32205092
[TBL] [Abstract][Full Text] [Related]
9. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
10. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
[TBL] [Abstract][Full Text] [Related]
11. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P;
Leukemia; 2021 Apr; 35(4):1121-1133. PubMed ID: 32814839
[TBL] [Abstract][Full Text] [Related]
12. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
13. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW
Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895
[TBL] [Abstract][Full Text] [Related]
14. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
15. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
Heidel F; Hochhaus A
Leukemia; 2020 Jul; 34(7):1723-1725. PubMed ID: 32528040
[No Abstract] [Full Text] [Related]
16. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
[TBL] [Abstract][Full Text] [Related]
17. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
Spinelli FR; Conti F; Gadina M
Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
19. JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Rojas P; Sarmiento M
Acta Haematol; 2021; 144(3):314-318. PubMed ID: 32726783
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
